Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.

ABSTRACT:

Background

Efgartigimod is a neonatal Fc receptor (FcRn) antagonist that reduces pathogenic IgG and improves clinical symptoms in generalized myasthenia gravis (gMG). However, its immunomodulatory effects on innate and adaptive immune cells beyond IgG depletion are rarely reported.

Objective

This study aimed to investigate clinical and immunological responses during the initial treatment cycle of efgartigimod in naive acetylcholine receptor antibody-positive (AChR-Ab+) gMG patients, with a focus on peripheral immune cell dynamics.

Methods

We conducted a longitudinal study between October 23, 2023, and December 10, 2024, based on the database of the Clinical Cohort Study of Myasthenia Gravis at Xuanwu Hospital, Capital Medical University. Seventeen naive AChR-Ab+ gMG p

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12518786 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature